about
Combination medical treatment for primary open angle glaucoma and ocular hypertension: a network meta-analysisWhere does selective laser trabeculoplasty stand now? A reviewSyncope and falls due to timolol eye drops.Cardiovascular safety of tiotropium Respimat vs HandiHaler in the routine clinical practice: A population-based cohort studyiStent as a Solo Procedure for Glaucoma Patients: A Systematic Review and Meta-Analysis.Selective laser trabeculoplasty as replacement therapy in medically controlled glaucoma patients.Cytotoxicity of pilocarpine to human corneal stromal cells and its underlying cytotoxic mechanisms.Graft failure: III. Glaucoma escalation after penetrating keratoplasty.Evaluation of risk of falls and orthostatic hypotension in older, long-term topical beta-blocker users.Optimization of methazolamide-loaded solid lipid nanoparticles for ophthalmic delivery using Box-Behnken design.Nightmare cessation following alteration of ophthalmic administration of a cholinergic and a beta-blocking agent.Systemic toxicity from ocular homatropine.Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension.Monozygotic twins concordant for both open-angle glaucoma and bronchospasm induced by beta-blockers.Switching patients with glaucoma or ocular hypertension from dual therapy to monotherapy: evaluation of brimonidine as a model.Acute care of the African American elder.Methazolamide-loaded solid lipid nanoparticles modified with low-molecular weight chitosan for the treatment of glaucoma: vitro and vivo study.Adverse effects using combined rate-slowing antihypertensive agents.Improved systemic safety and risk–benefit ratio of topical 0.1% timolol hydrogel compared with 0.5% timolol aqueous solution in the treatment of glaucoma
P2860
Q24192958-C66300C7-B68C-4F1F-A66F-DDFC6A302F67Q26751116-613E9EA2-9755-4E5E-BE0C-ACF5694DFDCEQ33153745-D3D4BE95-B59D-45E3-9D01-90BEF3338FD5Q33590384-A768055E-71E1-419A-B263-7B9C95AA35B5Q35644019-A6EF4622-A5C5-4991-AA44-B4C090BE003BQ36411219-AC9B8DE5-981C-4123-81FE-BC01006A8C13Q36858929-FF18BED7-E4B5-4473-90FF-E6B9DB5CD513Q37145908-264FA513-2A07-4974-8DD2-411261F44DAAQ37288495-4FF5919E-3D07-40C9-9013-DF683C03E271Q38194593-CC4AECE0-8FA8-4104-B01E-7B51112ADE81Q41108707-024AEF28-D6C5-442E-9F8D-236149454A82Q41165943-A2C28B0B-02F8-40F5-B53F-066225692860Q42075577-463B4A9A-8C29-4619-BA82-7657A62446D9Q43240207-C4954A5C-DD37-47FF-9E31-FC76448FE6D7Q43883442-CF8BF5B1-DDC4-4F43-B32D-33C24F009A62Q44404127-D5BD313B-659F-470C-A6E0-5249407993E1Q47447720-D5FCDEF4-8A99-46EE-9AB4-A5B15E0A4826Q48827251-E33C42FD-A55F-4960-BC04-20995AE5CECFQ57417579-3B7C8703-8BB1-4887-9879-0584BC2076F0
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 1990
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Systemic effects of medications used to treat glaucoma.
@en
Systemic effects of medications used to treat glaucoma.
@nl
type
label
Systemic effects of medications used to treat glaucoma.
@en
Systemic effects of medications used to treat glaucoma.
@nl
prefLabel
Systemic effects of medications used to treat glaucoma.
@en
Systemic effects of medications used to treat glaucoma.
@nl
P1476
Systemic effects of medications used to treat glaucoma.
@en
P2093
P304
P356
10.7326/0003-4819-112-2-120
P407
P577
1990-01-01T00:00:00Z